Oncobiologics (OTLK) Projected to Post Earnings on Thursday

Posted by Stanley Muller on Aug 6th, 2026

Oncobiologics (NASDAQ:OTLK – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect Oncobiologics to post earnings of ($0.09) per share and revenue of $0.9670 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Oncobiologics (NASDAQ:OTLK – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $4.39 million. On average, analysts expect Oncobiologics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncobiologics Stock Up 7.3%

OTLK opened at $1.03 on Thursday. The business has a 50 day moving average price of $1.28 and a two-hundred day moving average price of $0.68. The company has a market cap of $153.04 million, a PE ratio of -0.88 and a beta of 0.82. Oncobiologics has a 52 week low of $0.16 and a 52 week high of $3.39.

Insider Activity at Oncobiologics

In other news, Director Ghiath M. Sukhtian bought 8,539,709 shares of Oncobiologics stock in a transaction on Thursday, May 28th. The shares were bought at an average cost of $0.59 per share, for a total transaction of $5,038,428.31. Following the acquisition, the director owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. This trade represents a 63.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Faisal Ghiath Sukhtian acquired 95,398 shares of Oncobiologics stock in a transaction that occurred on Wednesday, July 29th. The shares were purchased at an average cost of $1.05 per share, for a total transaction of $100,167.90. Following the purchase, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This trade represents a 75.97% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 8,664,107 shares of company stock valued at $5,162,666 over the last 90 days. Insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Oncobiologics

A number of institutional investors have recently bought and sold shares of OTLK. Russell Investments Group Ltd. grew its holdings in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the period. AQR Capital Management LLC raised its holdings in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after buying an additional 44,063 shares in the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on OTLK shares. BTIG Research raised Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Monday, July 27th. Weiss Ratings cut Oncobiologics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Wall Street Zen raised Oncobiologics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. HC Wainwright boosted their target price on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Ascendiant Capital Markets upped their price target on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.65.

Get Our Latest Stock Report on OTLK

Oncobiologics Company Profile

(Get Free Report)

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.